http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103589676-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 |
| filingDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103589676-B |
| titleOfInvention | A kind of recombinant bacillus Calmette-Guerin vaccine rBCG::Rv3425 |
| abstract | The invention belongs to genetically engineered and bacille Calmette-Guerin vaccine technical field, be specially the recombinant bacillus Calmette-Guerin vaccine of a kind of tubercule bacillus.The widely used unique tuberculosis vaccine in the current whole world is BCG.Recombinant bacillus Calmette-Guerin vaccine of the present invention, is that tubercule bacillus rv3425 DNA recombinant expression is built acquisition in bacille Calmette-Guerin vaccine BCG, is designated as rBCG::Rv3425.After this new recombinant bacillus Calmette-Guerin vaccine immune mouse, CD4 in mouse peripheral bloodn + , CD8n + the lymphocytic ratio of T all obviously increases than BCG group, CD4n + , CD8n + t lymphocyte plays an important role in tuberculosis immunity.Therefore, recombinant bacillus Calmette-Guerin vaccine rBCG::Rv3425 may be used for the prevention of mycobacterium tuberculosis. |
| priorityDate | 2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.